Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Diagnostic method for behcet's disease using metabolome analysis

A technology for Behcet's disease and metabolites, applied in the field of diagnosis of Behcet's disease, can solve the problems of no diagnosis and prediction of Behcet's disease biomarker research reports, etc., to achieve rapid recovery of daily life, rapid treatment, and reduce long-term Effect

Pending Publication Date: 2019-12-06
KOREA UNIV RES & BUSINESS FOUND
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

(2010) Microbial Immunology (Microbiol Immunol) 54:354-361], and there is no research report on the discovery of biomarkers suitable for the diagnosis and prognosis of Behcet's disease using metabolomics

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diagnostic method for behcet's disease using metabolome analysis
  • Diagnostic method for behcet's disease using metabolome analysis
  • Diagnostic method for behcet's disease using metabolome analysis

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0061] Example 1: Identifying Metabolites Using GC / TOF MS

[0062] 20 microliters of blood each from the Behcet's disease patient group and healthy controls were mixed with 980 microliters of pure methanol, and the mixture was centrifuged to extract metabolites.

[0063] The derivatization process for GC / TOF MS is as follows.

[0064] Each extracted sample was dried in a speed bag, and then 5 μl of 40% (w / v) O-methylhydroxylamine hydrochloride in pyridine was added to it. ), so that they reacted for 90 minutes at 30° C. and 200 revolutions per minute (rpm). Then, 45 microliters of N-methyl-N-(trimethylsilyl)trifluoroacetamide (N-methyl-N-(trimethylsilyl)trifluoroacetamide) was added thereto so that they were heated at 37°C and React for 30 minutes at 200 rpm.

[0065] The instrument conditions of GC / TOF MS are as follows.

[0066] The column used for analysis is an RTX-5Sil MS capillary column (30 meters in length, 0.25 mm in film thickness and 25 mm in inner diameter), an...

example 2

[0071] Example 2: Differences in Metabolite Profiles in Blood Samples of Behcet's Disease Patients and Healthy Controls Using PLS-DA

[0072] The intensity of each metabolite identified according to Example 1 was divided by the sum of the intensities of all identified metabolites to normalize each metabolite. Subsequently, they were subjected to PLS-DA using SIMCA-P+ (version 12.0).

[0073] Such as figure 1 As shown, it was confirmed that there were significant differences in metabolite profiles in the blood samples of Behcet's disease patients and the blood samples of healthy controls.

[0074] Table 2 shows VIP values ​​and loading values, which represent the degree and direction of influence of the 104 metabolites used in the PLS-DA model on the model.

[0075] [Table 2]

[0076]

[0077]

[0078]

[0079]

[0080]

example 3

[0081] Example 3: Selection of Behcet's Disease Patient-Specific Biomarker Metabolites

[0082] In order to find biomarkers that showed a specific increase or decrease in Behcet's disease patients, VIP values, fold changes, AUC values ​​and p-values ​​affecting the difference in the metabolomic profile of each metabolite obtained from Example 2 were obtained. A VIP value of 1.5 or greater than 1.5, a fold change of 1.2, an AUC value of 0.800 or greater than 0.800, and a p value of less than 0.01 were set as the reference values ​​for each metabolite, and 13 metabolites showed positive effects on diagnosis Behcet's disease applicability (see Table 3). In addition, the absolute intensities of these metabolites were compared by group (see figure 2 ).

[0083] Table 3 below shows the VIP value, AUC value, fold change (fold change) and p value (BD: Behcet's disease patient; control : healthy individuals).

[0084] [table 3]

[0085]

[0086] AUC, area under the ROC curve; ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a diagnostic method for Behcet's disease using metabolome analysis and provides a biomarker with which Behcet's disease can be effectively diagnosed using metablomics,and which can be applied to the development of a therapeutic agent for Behcet's disease.

Description

technical field [0001] The present invention relates to a method for diagnosing Behcet's disease through metabolomic analysis. Background technique [0002] Behçet's disease is a systemic vasculitis of unknown etiology characterized by symptoms such as oral, genital, and anal ulcers, uveitis, arthritis, and disease invasion of vital organs (e.g., gastrointestinal tract, blood vessels and central nervous system, etc.). Behcet's disease has been reported to occur more frequently from the Mediterranean coast to Far East Asia, especially in Korea, China, Japan, and Turkey. [0003] Behcet's disease has a very variable clinical presentation and can be associated with mild symptoms (eg, recurrent oral ulcers) and fatal sequelae (eg, blindness, intestinal ulceration and perforation, hemoptysis due to aneurysm, deep vein thrombosis, and hemiplegia) ), the sequelae are caused by the disease invading the eyeball, gastrointestinal tract, blood vessels and central nervous system. The...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/50A61B5/145G01N30/72G01N30/88
CPCA61B5/145A61B5/14546G01N33/6842G01N33/6848G01N33/6893G01N2570/00G01N2800/7095G01N30/7206G01N33/50G01N2030/8822G01N2800/328G01N2560/00
Inventor 金京宪车勋锡金净衍安重敬
Owner KOREA UNIV RES & BUSINESS FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com